close :

:

Forgotten your password?
 
Clinical Trials
Printable Version   Email to a friend

Sarasota's Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Findings Detailed in The Journal of Clinical Investigation

SARASOTA, Fla., Aug 1 /PRNewswire/ -- The Roskamp Institute today released a study defining a mechanism for the development of obesity and the metabolic syndrome, which are the forerunners of type 2 diabetes. The study, led by Roskamp's Dr. Robert Farese, is detailed in the August issue of The Journal of Clinical Investigation, a highly prestigious medical research journal.

While the Roskamp Institute's primary focus is on Alzheimer's disease, Roskamp researchers have a significant interest in diabetes due to studies that suggest those who have diabetes are more likely to develop Alzheimer's disease.

The study found that a deficiency in an enzyme, atypical protein kinase C, impairs the ability of insulin to stimulate glucose uptake into the muscle, which produces a state of resistance to circulating insulin. Once this occurs, the liver begins to produce excessive quantities of fat, causing abdominal obesity and alterations in blood lipids. According to the study, this can then lead to obesity and the metabolic syndrome, the precursors of type 2 diabetes.

"Although this gene-knockout study was done on mice, it is particularly relevant to type 2 diabetic humans, who are known to have deficiencies of this enzyme in their muscles," said Dr. Farese. "The findings showed that in the mice a simple loss of one or more genes that are responsible for the production of this enzyme could eventually cause obesity and the metabolic syndrome which then could lead to type 2 diabetes."

Further research must be done to determine how human diabetics acquire a deficiency of this enzyme in their muscles; however, this mouse model should be especially helpful to further study and devise treatments for obesity and the metabolic syndrome.

"We are particularly excited about this study and the potential to develop treatments for obesity and the metabolic syndrome, which are both global health problems," said Dr. Michael Mullan, director of the Roskamp Institute. "This study will also be helpful in further determining how obesity, the metabolic syndrome and type 2 diabetes are linked to Alzheimer's disease."

The study was co-authored by Dr. Farese, who led the team of Mini P. Sajan, Hong Yang, and Sonali Nimal at the Roskamp Institute; and others at the James A. Haley Veterans Administration Medical Center in Tampa; the University of South Florida College of Medicine; the Joslin Research Foundation and Harvard University School of Medicine; Yale University School of Medicine, and Research Center at Oslo, Norway.

CONTACT: Sarah Bascom or Kristen Bridges

            (850) 222-2140


    For more information regarding this study or the Roskamp Institute, please

contact Dr. Farese at (941) 752-2949, or visit

http://www.RoskampInstitute.com .

CONTACT: Sarah Bascom or Kristen Bridges, both of DC Navigators,+1-850-222-2140, or Dr. Farese of The Roskamp Institute, +1-941-752-2949

Web site: http://www.RoskampInstitute.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Clinical Trial Results...

Clinical Trial Results Archive

2008: Jan | Feb | Mar | Apr | May
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec

More News Resources


Join Drugs.com
Click here to see what benefits you can get by joining our FREE membership programme.
Drugs.com is the most popular, comprehensive, and up-to-date source of drug information online. Providing advice on more than 24,000 prescription drugs and over-the-counter medicines for consumers and professionals .
Advertisement
In The Pipeline